05:29 , Jul 31, 2019 |  BioCentury  |  Finance

How Wellington closed its largest fund yet at €210M

Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria and Switzerland, helped Wellington Partners raise its largest fund to date. Wellington announced Wednesday the close of Wellington Partners...
22:41 , Jun 4, 2019 |  BC Extra  |  Company News

Management tracks: Vericel, Theravance, Eisai

Cell therapy company Vericel Corp. (NASDAQ:VCEL) disclosed in an SEC filing that Daniel Orlando resigned as COO on May 28 to become CEO of a private biotech company. SVP, Quality and Regulatory Affairs Michael Halpin...
00:27 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
23:41 , Feb 7, 2019 |  BC Innovations  |  Finance

Pharma ventures earlier

Facing the squeeze from inside and out, at least three corporate venture arms are revamping operations to increase their foothold in earlier and riskier investment opportunities. From one side, the move reflects the growing reliance...
19:48 , Jun 29, 2018 |  BioCentury  |  Finance

Carisma’s attraction

Macrophage immunotherapy play Carisma Therapeutics Inc. has developed biomarkers that it can use to track macrophage activity and tumor response in preclinical and clinical studies, leading Wellington Partners to join its $53 million series A...
14:52 , Jun 29, 2018 |  BC Week In Review  |  Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by existing investors AbbVie Ventures and HealthCap. Existing investors IP Group plc (LSE:IPO), Penn Medicine and Grazia Equity,...
04:01 , Jun 27, 2018 |  BC Extra  |  Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by existing investors AbbVie Ventures and HealthCap. Existing investors IP Group plc (LSE:IPO), Penn Medicine and Grazia Equity,...
05:08 , Jun 16, 2017 |  BC Week In Review  |  Financial News

Carma raises venture funding

On June 12, Carma Therapeutics Inc. (Philadelphia, Pa.) raised an undisclosed amount in an "initial" round of financing co-led by AbbVie Ventures and HealthCap. Grazia Equity and IP Group plc (LSE:IPO) also participated. Carma is...
19:46 , Jun 12, 2017 |  BC Extra  |  Financial News

Carma raises venture funding

Carma Therapeutics Inc. (Philadelphia, Pa.) said it raised an undisclosed amount in an "initial" round of financing co-led by AbbVie Ventures and HealthCap. Grazia Equity and IP Group plc (LSE:IPO) also participated. The company, which...
13:17 , May 18, 2017 |  BC Innovations  |  Emerging Company Profile

Spreading Carma

Carma Therapeutics LLC is subverting macrophages’ tumor-promoting role by engineering in chimeric antigen receptors (CARs) to turn the phagocytic cells into agents that suppress the growth of solid tumors. The company is a translational play...